StockWatch
·
Q2 FY-2027 RESULTS · BOROSCI

Borosil Scientific Q2FY27: PAT +86% YoY to ₹5.3 Cr, margin expands as pharma losses narrow

PAT +86.37% YoY · revenue +7.55% · margins expanding

Q2 FY27 resultsBOROSCIBorosil Scientific Ltd28 Oct 2026 · 3 min read
Revenue

₹114.96 Cr

+7.55% YoY

PAT (consolidated)

₹5.31 Cr

+86.37% YoY

Net margin

4.52%

+1.9pp YoY

EPS

₹0.6

On a consolidated basis — the primary basis for this group — Borosil Scientific's Q2 FY27 (quarter ended 30 Sept 2026) PAT rose 86.4% YoY to ₹5.31 Cr (EPS ₹0.60 vs ₹0.32) on revenue up 7.5% YoY to ₹114.96 Cr, with NPM expanding to 4.52% from 2.61% and OPM (EBITDA margin) to 9.31% from 7.51% a year ago. But this headline needs an immediate caveat: standalone (parent-only) PAT actually fell 16.9% YoY to ₹6.25 Cr from ₹7.52 Cr, even as standalone revenue grew 4.7% YoY to ₹104.19 Cr — so the consolidated growth is driven almost entirely by subsidiary Goel Scientific Glass Works narrowing its quarterly net loss to ₹0.85 Cr (per the auditor's note) from an estimated ~₹4.7-5.1 Cr a year ago (back-calculated from the Scientific segment's standalone-vs-consolidated gap), not by stronger parent profitability.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹114.96 Cr+7.7%+7.5%
Expenses₹109.7 Cr+6.1%+5.6%
PAT₹5.31 Cr+21.85%+86.37%
Net margin4.52%+0.5pp+1.9pp
EPS₹0.6+22.4%+87.5%

The margin bridge has two real, non-subsidiary drivers worth separating from the consolidation effect: the Primary Pharma Packaging segment's loss narrowed to ₹2.60 Cr from ₹5.13 Cr YoY at both standalone and consolidated levels — a genuine structural improvement — while Consumer Glassware revenue fell 10.2% YoY to ₹14.96 Cr with segment profit down to ₹0.78 Cr from ₹1.06 Cr. Working against the group, the standalone Scientific – Lab Glass & Equipment segment's own profit contracted 20.3% YoY (₹18.06 Cr to ₹14.40 Cr segment PBT) despite its revenue growing, pointing to cost or mix pressure in the core parent business that the consolidated optics mask.

₹
96.05113.1130.15147.2164.25109.9507-2708-1809-0910-0510-28Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹109.95, down 4.8% over the past month of trading.

₹ Cr
-7.985.0218.0231.02-4.21Q1 FY26rev ₹96 Cr2.85Q2 FY26rev ₹107 Cr8.7Q3 FY26rev ₹121 Cr27.25Q4 FY26rev ₹143 Cr4.36Q1 FY27rev ₹107 Cr5.31Q2 FY27rev ₹115 Cr
Quarterly consolidated PAT, ₹ Crore

No street consensus or formal brokerage preview for this quarter turned up in search, and our records and the filing carry no prior management guidance to grade the print against — both angles are genuinely unavailable rather than skipped. No separate press release was available to cross-check management's own framing of the quarter. The results were approved alongside two capex moves: a ₹70 Cr Borosilicate 3.3 glass tubing furnace (20 MT/day) at Bharuch, intended to backward-integrate tubing currently imported for Pharma Packaging, with commercial production targeted by March 2028; this follows the September 22 announcement of a 7x capacity expansion to 108 lakh units and a separate ₹60 Cr Gujarat facility. Both capex items are funded via internal accruals/borrowings and sit outside this quarter's P&L.

  • W1

    Execution of the ₹70 Cr Bharuch glass-tubing furnace (20 MT/day, commercial production targeted March 2028) — watch capex drawdown pace and any margin uplift to Pharma Packaging once online

  • W2

    Standalone Lab Glass segment profit contracted 20.3% YoY this quarter — watch whether this core-business margin pressure persists or reverses next quarter

  • W3

    Subsidiary Goel Scientific Glass Works' loss narrowed to ₹0.85 Cr this quarter from a much larger year-ago drag — watch whether it continues toward breakeven or re-widens

Figures converted from lakhs; consolidated PAT (530.66L) is pre-NCI 'profit for period', matching the convention used in comparison-context figures. No exceptional item in current or year-ago quarter (H1 FY26's 661.31L VRS exceptional was booked in Q1 FY26). Consolidated includes subsidiary Goel Scientific Glass Works (Q2FY27 net loss 84.87L vs an estimated ~467L loss a year ago per segment-level back-calculation), which materially diverges the consolidated growth story from standalone.

Informational and educational content only. Not investment advice.